Enovis Corp (ENOV) Stock Forecast & Price Target

Enovis is viewed positively because its mix shift toward higher-growth, higher-margin Reconstructive products should lift revenue, gross margin, and operating leverage, with EBITDA and EPS expected to grow faster than sales. The company’s 2Q26 results were solid, with revenue of $582.8M, 4.8% organic growth, Recon up 8% Y/Y, P&R still producing steady cash flow, and free cash flow improving by $31M. Management also reaffirmed FY26 guidance of $2.31B-$2.37B revenue, $425M-$435M adj. EBITDA, and ~$3.52-$3.73 adj. EPS, while valuation remains compelling at below 7x NTM EV/EBITDA.

Enovis is facing a deteriorating fundamental outlook as its planned eCential Robotics acquisition is expected to dilute adjusted EBITDA margin by about 150 bps in 2027, only partly offset by 50 bps of underlying improvement, leaving a net 100 bps drag. The model revisions reflect this pressure, with 2027E adjusted EBITDA cut to $422M from $470M and adjusted EPS reduced to $3.45 from $4.06, while the bear case assumes revenue growth below 4% and earnings that fall below consensus. Competitive and regulatory risks also intensify, including slower orthopedic growth, tariff pressure, potential market share loss in robotic systems, and bone growth stimulation reclassification that could open the market to new entrants and pressure pricing on a business representing roughly 6% of FY25 revenue.